A Quarterly report that identifies Suitability Filings for that quarter. It also offers insight into the possible alterations proposed in the filing.
This report identifies new Suitability Petitions filed, rejected and/or approved by the USFDA. The report includes the reason for Suitability Petition along with the USFDA document published on that Suitability Petition.
Please find attached the report on list of drugs with
Suitability Petitions activities for the month of September 2024 (filed /
accepted / rejected / approved). The current month report covers the below
products:
Please find attached the report on list of drugs with Suitability Petitions activities for the month of October 2024 (filed / accepted / rejected / approved). The current month report covers the below products:
Please find attached the report on list of drugs with
Suitability Petitions activities for the month of September 2024 (filed /
accepted / rejected / approved). The current month report covers the below
products:
1.
Cyproheptadine Hydrochloride
2.
Amlodipine; Hydrochlorothiazide; Valsartan
3.
Omeprazole and Sodium Bicarbonate
4.
Triamcinolone Acetonide
5.
Cisatracurium Besylate
6.
Midodrine Hydrochloride
7.
Dapsone
8.
Lidocaine
9.
Levothyroxine Sodium
10.
Bupivacaine Hydrochloride
11.
Levetiracetam In Sodium Chloride
12.
Vasopressin
13.
Metronidazole
14.
Hydromorphone Hydrochloride